Omniscope launches osLongevity in pivot from immune system research applications into consumer longevity and prevention.
TechBio startup Omniscope has launched osLongevity, a platform designed to track and optimize aging by analyzing the immune system at the cellular level. The Barcelona-based company claims its subscription-style platform profiles an individual’s immune system at single-cell resolution to produce a dynamic measure of biological age and guide interventions intended to preserve physical and cognitive function.
Founded in 2020 by Professor Holger Heyn, Vijay Vaswani and Lynnette Ang, Omniscope says osLongevity is a deliberate shift from its prior focus on research tools towards consumer and clinician-facing applications. The new tool extends the company’s immune-profiling and AI analytics capabilities into longevity and preventive care.
“The immune system is one of the most dynamic and responsive indicators of how we’re aging,” said Heyn, who leads the Single Cell Genomics Group at the Spanish National Center for Genomic Analysis, one of Europe’s largest genomics facilities. “With osLongevity, we can see the effects of lifestyle and interventions in near real time and guide people toward actions that help preserve health and extend vitality.”
Omniscope’s technology has already been deployed in elite sports through a collaboration with soccer giant FC Barcelona, where its immune profiling tools have been used to track resilience, inflammation and recovery. With osLongevity, the same methods, adapted from clinical trials and peer-reviewed research, are now aimed at broader healthspan applications.
Vijay Vaswani (center) is the CEO of Omniscope
osLongevity aims to shift the focus from fragmented wellness data, such as heart rate readings, to a more comprehensive model of aging that can be queried in real time. Central to the platform is its Immune Age feature, a dynamic measure of immune health relative to chronological age that responds to factors such as training, recovery, illness, diet and medical interventions.
According to the Omniscope web site, the platform incorporates multiple additional measures relevant to longevity, including an “inflammaging” assessment, measuring the chronic, low-grade inflammation linked to accelerated aging and disease risk. The tool’s “protection score” quantifies immune system strength, while an immune tracking feature offers an ongoing view of immune responses over time. Cellular senescence is measured to identify the buildup of inactive but inflammatory cells that contribute to tissue damage and aging, and telomere length is also tracked as an indicator of cellular resilience and regenerative potential. Finally, a methylation clock provides an additional layer of insight into an individual’s biological age.
“osLongevity combines deep immune science with practical, personalized insights,” said Omniscope CEO Vaswani. “Built on the same platform that has advanced breakthrough immunotherapies, it empowers consumers to see how diet, exercise, sleep, and other lifestyle choices impact their longevity. Importantly, this also gives healthcare professionals a powerful ‘cellular avatar’ to deliver truly personalized, data-driven care.”
Omniscope is backed by Silicon Valley VC FoundersX Ventures, the lead investor in its undisclosed seed round.
“Omniscope’s osLongevity is a big leap in preventive healthcare, harnessing GenAI and high-throughput single-cell TCR sequencing to track immune age in real time,” said FoundersX managing partner Helen Liang. “By empowering individuals to understand how lifestyle impacts their biological aging, osLongevity puts the power of everyone’s health in his or her own hands, paving the way for a future where staying young and healthy is a choice driven by data and science.”